预防性葡萄糖凝胶用于新生儿低血糖的成本效用分析
该成本效用分析从卫生系统视角,采用决策树模型评估对有新生儿低血糖风险的婴儿使用预防性葡萄糖凝胶与标准护理的长期成本和生命质量影响。结论认为预防性策略可能更具成本效益。
要点
- 预防性葡萄糖凝胶组累积11.25 QALYs,标准护理组11.10 QALYs。
- 对有低血糖风险的婴儿,预防性葡萄糖凝胶可能具有成本效益。
核心结论
- 对有新生儿低血糖风险的婴儿,预防性使用葡萄糖凝胶相比标准护理可能更具成本效益。
研究设计与样本
- 从卫生系统视角开展的成本效用分析,使用决策树模型模拟新生儿低血糖的长期临床结局。
- 模型参数(如低血糖和新生儿重症监护室入住概率)基于Hypoglycemia Prevention with Oral Dextrose Study研究前的数据。
- 长期结局概率和成本基于已发表文献综述估计。
临床怎么用
- 对于有新生儿低血糖风险的婴儿,可考虑预防性使用葡萄糖凝胶以可能降低长期卫生系统成本并改善生命质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term costs and impact on quality of life of using prophylactic dextrose gel in patients at increased risk of developing neonatal hypoglycemia. STUDY DESIGN: A cost-utility analysis was performed from the perspective of the health system, using a decision tree to model the long-term clinical outcomes of neonatal hypoglycemia, including cerebral palsy, epilepsy, vision disturbances, and learning disabilities, in patients at increased risk of neonatal hypoglycemia who received prophylactic dextrose gel vs standard care. Model parameters including likelihoods of hypoglycemia and admission to a neonatal intensive care unit, were based on the pre-Hypoglycemia Prevention with Oral Dextrose Study. Estimations of the likelihood of long-term condition(s), and their costs, were based on review of published literature. RESULTS: Patients who received prophylactic dextrose gel incurred costs to the health system of around US $14 000 over an 18-year time horizon, accruing 11.25 quality-adjusted life-years, whereas those who did not receive prophylactic treatment incurred cost of around $16 000 and experienced a utility of 11.10 quality-adjusted life-years. CONCLUSIONS: A prophylactic strategy of using dextrose gel in infants at increased risk of neonatal hypoglycemia is likely to be cost effective compared with standard care, to reduce the direct costs to the health system over an 18-year time horizon, and improve quality of life.
引用
- Glasgow MJ, Edlin R, Harding JE, et al. Cost-Utility Analysis of Prophylactic Dextrose Gel vs Standard Care for Neonatal Hypoglycemia in At-Risk Infants. J Pediatr. 2020. PMID: 32634402. doi:10.1016/j.jpeds.2020.06.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。